Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cabergoline (FCE-21336) 是一种麦角衍生的多巴胺 D2亚类受体激动剂,高亲和力作用于D2、D3和5-HT2B 受体,Ki 分别为 0.7、1.5 和 1.2。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 285 | 现货 | ||
5 mg | ¥ 672 | 现货 | ||
10 mg | ¥ 996 | 现货 | ||
25 mg | ¥ 2,160 | 现货 | ||
50 mg | ¥ 3,320 | 现货 | ||
100 mg | ¥ 4,730 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 738 | 现货 |
产品描述 | Cabergoline (FCE-21336) is an ergot derived-dopamine D2-like receptor agonist. It has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively).Cabergoline permits rapid and effective hormonal and tumor control by normalizing prolactin-producing pituitary adenomas levels. |
体外活性 | Cabergoline(10 μM) is used to investigate its neuroprotective effects. MAP2 staining reveals that Cabergoline significantly suppresses the loss of neurons caused by H2O2 incubation. Pretreatment with Cabergoline inhibits H2O2-induced neuronal cell death in a dose-dependent manner. Cabergoline prevents apoptotic cell death following H2O2 exposure [1]. |
体内活性 | Cabergoline has a longer elimination half-life (63 to 109 h) compared with other D2-like receptor agonists, both a long-lasting clinical effect following single-dose administration. And an improvement in the quality of life of patients with chronic diseases is expected [1]. The most significant reduction in rapid eye movement (REM) sleep bout number occurred during the light phase. In which Cabergoline-injected female handled mice has 67.3% less REM sleep bouts (F(1,11)=12.892, P=0.004) than Cabergoline-injected females that are restrained, although the greatest number in the reduction of REM sleep bouts occur during the dark phase (82.3% fewer REM sleep bouts; F(1,11)=3.667, P=0.082). In male mice, Cabergoline reduces baseline Prolactin (PRL) levels (98.5%; F(1,6)=13.192, P=0.011) from 5.8±1.3 to 0.08 ng/mL within 2 hours of injection. PRL levels return to values that are not different from baseline (5.0±0.60 ng/mL; F(1,6)=0.715, P=0.43), after a 7-day recovery period [2]. |
别名 | FCE-21336, 卡麦角林 |
分子量 | 451.6 |
分子式 | C26H37N5O2 |
CAS No. | 81409-90-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 32 mg/mL(70.86 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2143 mL | 11.0717 mL | 22.1435 mL | 55.3587 mL |
5 mM | 0.4429 mL | 2.2143 mL | 4.4287 mL | 11.0717 mL | |
10 mM | 0.2214 mL | 1.1072 mL | 2.2143 mL | 5.5359 mL | |
20 mM | 0.1107 mL | 0.5536 mL | 1.1072 mL | 2.7679 mL | |
50 mM | 0.0443 mL | 0.2214 mL | 0.4429 mL | 1.1072 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Cabergoline 81409-90-7 Autophagy GPCR/G Protein Neuroscience Dopamine Receptor 5-HT Receptor FCE-21336 FCE 21336 FCE21336 inhibit Inhibitor 卡麦角林 inhibitor